share_log

醫思健康：截至2024年3月31止月份之股份發行人的證券變動月報表

EC HEALTHCARE: Monthly Return of Equity Issuer on Movements in Securities Ended 31 March 2024

香港交易所 ·  Apr 8 05:24
Summary by Moomoo AI
醫思健康（EC HEALTHCARE）於2024年4月8日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年3月31日的公司股份及證券變動情況。報告顯示，公司法定/註冊股本結存維持在38,000,000,000股，每股面值0.00001港元，總額380,000港元，本月無增減變動。股份期權方面，根據2016年及2023年通過的購股權計劃，本月內無股份期權變動，且無新股份因行使期權而發行。權證方面，包括OrbiMed認股權證及買賣協議中的認股權證，本月內因此發行的發行人新股份數目分別為5,899,513股及6,000,000股。可換股票據方面，包括GS及OrbiMed可換股債券，本月內因此發行的發行人新股份數目分別為41,493,930股及5,483,304股。報告亦確認，所有證券發行均已獲董事會批准，並符合香港聯合交易所有限公司證券上市規則的要求。
醫思健康（EC HEALTHCARE）於2024年4月8日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年3月31日的公司股份及證券變動情況。報告顯示，公司法定/註冊股本結存維持在38,000,000,000股，每股面值0.00001港元，總額380,000港元，本月無增減變動。股份期權方面，根據2016年及2023年通過的購股權計劃，本月內無股份期權變動，且無新股份因行使期權而發行。權證方面，包括OrbiMed認股權證及買賣協議中的認股權證，本月內因此發行的發行人新股份數目分別為5,899,513股及6,000,000股。可換股票據方面，包括GS及OrbiMed可換股債券，本月內因此發行的發行人新股份數目分別為41,493,930股及5,483,304股。報告亦確認，所有證券發行均已獲董事會批准，並符合香港聯合交易所有限公司證券上市規則的要求。
EC HEALTHCARE SUBMITTED ITS LATEST SECURITIES MONTHLY CHANGE REPORT TO HONG KONG TRADING AND SETTLEMENT LIMITED ON 8 APRIL 2024, REPORTING THE CHANGES IN COMPANY SHARES AND SECURITIES AS OF 31 MARCH 2024. The report showed that the company's regulated/registered share capital remained at 38,000,000,000 shares with a face value of HK$0.00001 per share for a total of HK$380,000, unchanged this month. In terms of share options, under the share option plans adopted in 2016 and 2023, no share options were changed during the month and no new shares were issued as a result of the exercise of options. In terms of warrants, including OrbiMed warrants and warrants included in the purchase and sale agreement, the number of issuer new shares issued this month was...Show More
EC HEALTHCARE SUBMITTED ITS LATEST SECURITIES MONTHLY CHANGE REPORT TO HONG KONG TRADING AND SETTLEMENT LIMITED ON 8 APRIL 2024, REPORTING THE CHANGES IN COMPANY SHARES AND SECURITIES AS OF 31 MARCH 2024. The report showed that the company's regulated/registered share capital remained at 38,000,000,000 shares with a face value of HK$0.00001 per share for a total of HK$380,000, unchanged this month. In terms of share options, under the share option plans adopted in 2016 and 2023, no share options were changed during the month and no new shares were issued as a result of the exercise of options. In terms of warrants, including OrbiMed warrants and warrants included in the purchase and sale agreement, the number of issuer new shares issued this month was 5,899,513 shares and 6,000,000 shares, respectively. In terms of convertible securities, including GS and OrbiMed convertible bonds, the number of issuer new shares issued this month was 41,493,930 shares and 5,483,304 shares, respectively. The report also confirms that all securities issues have been approved by the Board of Directors and comply with the requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more